Analyst Expectations for Theseus Pharmaceuticals's Future
Portfolio Pulse from Benzinga Insights
Analysts have given Theseus Pharmaceuticals (NASDAQ:THRX) mostly bullish ratings in the last quarter, with a total of 6 bullish and 2 somewhat bullish ratings. The company has an average price target of $17.0, representing a 26.09% decrease from the previous average price target of $23.00.
July 14, 2023 | 1:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Theseus Pharmaceuticals has received mostly bullish ratings from analysts, but the average price target has decreased by 26.09%.
While the bullish ratings indicate a positive outlook for Theseus Pharmaceuticals, the decrease in the average price target suggests that analysts expect the stock price to decrease in the future. This could potentially lead to a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100